Autolus Therapeutics Reports Strong Start in 2025 with AUCATZYL® Launch and Expanding Trials
Autolus Therapeutics PLC reported a promising start to 2025, with its flagship product AUCATZYL generating $9.0 million in net product revenue and receiving conditional marketing authorization in the UK.
3 minutes to read